On May 31st, 2019, the FDA held a public hearing, “to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.”
In advance of this hearing, the CNF Board of Directors formally submitted the following statement to the FDA.
